8 completed, 3 active not recruiting, 1 terminated. 7 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Pigmented Villonodular Synovitis: new trials by email Literature Review of Pigmented Villonodular Synovitis trials Research Report on Pigmented Villonodular Synovitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Abbisko Therapeutics Co, Ltd | 94 | 2023-04-27 | 2026-05-04 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor Vimseltinib, Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 123 | 2021-10-14 | 2026-03-20 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| Screening of Specific Genes for Pigmented Villous Nodular Synovitis Arthroscopic synovectomy - Pigmented Villonodular Synovitis | Completed | Peking University Third Hospital | 60 | 2020-08-03 | 2021-07-08 | |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
| Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Pexidartinib, Placebo - Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath | Phase 3 | Completed | Daiichi Sankyo | 120 | 2015-05-11 | 2022-05-11 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2012-04-23 | 2021-01-05 |
| Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease Synovitis diagnosis - Synovial Diseases, Pigmented Villonodular Synovitis | Completed | Peking University Third Hospital | 350 | 2012-01-01 | 2022-11-02 | |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Tasigna - Pigmented Villonodular Synovitis | Phase 2 | Completed | Centre Leon Berard | 50 | 2010-12-01 | 2013-04-16 |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor nilotinib - Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Completed | Andrew J. Wagner, MD, PhD | 17 | 2010-09-01 | 2026-02-20 |
Synovitis, Pigmented Villonodular (12) · Giant Cell Tumor of Tendon Sheath (9) · Arthritis, Rheumatoid (1) · Gout (1)
Giant Cell Tumors (12) · Joint Diseases (12) · Muscular Diseases (12) · Musculoskeletal Diseases (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Synovitis (12) · Tendinopathy (12) · Giant Cell Tumor of Tendon Sheath (3) · Arthritis (1) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1)
nilotinib (2) · cabiralizumab (1) · pexidartinib (1)
AmMax Bio, Inc. (2) · Deciphera Pharmaceuticals, LLC (2) · Peking University Third Hospital (2) · Abbisko Therapeutics Co, Ltd (1) · Andrew J. Wagner, MD, PhD (1) · Centre Leon Berard (1) · Daiichi Sankyo (1) · Five Prime Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1)
United States (8) · Netherlands (7) · Poland (7) · France (5) · Italy (5) · United Kingdom (5) · Australia (4) · Canada (4) · Spain (4) · China (3) · Germany (2) · Hungary (2) · Switzerland (2) · Denmark (1) · Hong Kong (1)
Dorothy Nguyen, MD (2) · Andrew J. Wagner, MD, PhD (1) · Jean Yves Blay, PR (1) · Maitreyi Sharma, MD (1) · Yingfang Ao, Prof. (1)
PMID 27041409, PMID 29571946, PMID 31229240, PMID 32755241, PMID 33289960, PMID 35932628, PMID 36001000, PMID 37593881, PMID 38843860, PMID 39287124, PMID 41796601, PMID 42132251, PMID 42872549
2014 (1)